Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19

Area of Science:

• Immunology
• Infectious Diseases
• Critical Care Medicine

Background:

• COVID-19 is characterized by a hyperinflammatory state involving elevated cytokines.
• Interleukin-6 (IL-6) is a key driver of this inflammation, and targeted therapies like tocilizumab are used.
• The role of other cytokines, such as soluble IL-2 receptor (sIL2R) and IL-10, in disease progression and treatment response requires further investigation.

Purpose of the Study:

• To analyze cytokine profiles (IL-6, sIL2R, IL-10) in hospitalized COVID-19 patients.
• To evaluate the impact of immune-modulating therapies (tocilizumab and glucocorticoids) on these cytokine levels.
• To explore the potential of sIL2R and IL-10 as markers of immune dysregulation post-IL-6 inhibition.

Main Methods:

• Retrospective chart review of adult patients with moderate to critical COVID-19.
• Classification of disease severity based on oxygen requirements.
• Measurement of IL-6, sIL2R, and IL-10 levels before and after treatment with tocilizumab and/or glucocorticoids.

Main Results:

• Elevated IL-6, sIL2R, IFN-γ, and IL-10 were common in COVID-19 patients.
• Tocilizumab treatment led to significant increases in IL-6 and sIL2R, while IL-10 decreased in severe cases.
• Higher admission IL-6, sIL2R, CRP, and D-dimer levels were associated with increased disease severity and mortality.

Conclusions:

• Clinical cytokine monitoring can aid in assessing treatment response in COVID-19.
• The rise in sIL2R post-tocilizumab suggests that combination therapies may be necessary to fully modulate hyperinflammation.
• Cytokines may serve as biomarkers for guiding the use of adjunctive glucocorticoid therapy.